AstraZeneca PLC (LON:AZN) Bevespi Aeroshere (glycopyronium/formoteral fumarate) has been approved in China as a maintenance treatment to relieve symptoms in patients with chronic obstructive pulmonary disease..

AstraZeneca PLC (LON:AZN) and Daiichi Sankyo Company, Limited’s Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of patients..

AstraZeneca plc (LON:AZN) Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular death and hospitalisation for heart failure in adults with..

AstraZeneca PLC (LON:AZN) and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced further positive results..

AstraZeneca plc (LON:AZN) ADAURA Phase III trial for Tagrisso (osimertinib) in the adjuvant treatment of patients with Stage IB, II and IIIA epidermal growth factor receptor-mutated..

AstraZeneca PLC (LON:AZN) Imfinzi (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in..

AstraZeneca PLC (LON:AZN) Lokelma (sodium zirconium cyclosilicate) has been approved in Japan for the treatment of patients with hyperkalaemia (elevated levels of potassium in the blood)...

AstraZeneca plc (LON:AZN) today announced that Lynparza (olaparib) has been granted orphan drug designation (ODD) in Japan for the maintenance treatment of germline BRCA-mutated (gBRCAm) curatively..

AstraZeneca PLC (LON:AZN) has today announced that Imfinzi confirmed a sustained overall survival benefit in final analysis of the Phase III CASPIAN trial in 1st-line extensive-stage..

AstraZeneca (LON:AZN) and MSD Inc (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced high-level results from the Phase III GY004..

AstraZeneca PLC (LON:AZN) has today updated on the Phase III DANUBE trial in bladder cancer. The Phase III DANUBE trial for Imfinzi (durvalumab) and Imfinzi plus tremelimumab in unresectable, Stage..

AstraZeneca (LON:AZN) today announced that it has completed the previously communicated agreement with Atnahs Pharma to divest its global commercial rights to Inderal (propranolol), Tenormin (atenolol),..

AstraZeneca (LON:AZN) has today announced that it has agreed to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill)...

AstraZeneca plc (LON:AZN) has today announced its full year and Q4 2019 results. AstraZeneca delivered a year of strong revenue growth, supported by the launch of..

High-level results from the Phase III THALES trial showed AstraZeneca (LON:AZN) Brilinta (ticagrelor) 90mg used twice daily and taken with aspirin for 30 days, reached a..

High-level results from the positive registrational Phase II trial DESTINY-Gastric01 showed AstraZeneca (LON:AZN) and Daiichi Sankyo Company, Limited’s Enhertu, achieved a statistically significant and clinically meaningful improvement..

AstraZeneca (LON:AZN) Imfinzi (durvalumab) and tremelimumab, an anti-CTLA4 antibody and potential new medicine, have both been granted Orphan Drug Designation (ODD) in the US for the..

AstraZeneca (LON:AZN) and MSD Inc., Kenilworth, N.J., US (known as Merck & Co., Inc. inside the US and Canada) today announced that a supplemental New Drug..

Following the recommendation from an independent Data Monitoring Committee, AstraZeneca (LON:AZN) has decided to close the Phase III STRENGTH trial for Epanova (omega-3 carboxylic acids) due..

AstraZeneca (LON:AZN) and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) has today announced that a supplemental..